Breast: Surgical Treatment
Risk-Reducing (Prophylactic) Surgery
Breast Cancer Prophylaxis
- Risk-Reducing (Prophylactic) Bilateral Mastectomy Indications:
- Lifetime Risk of Breast Cancer Calculated ≥ 25%
- High-Risk Genetic Mutation (BRCA1, BRCA2, PALB2, TP53 or PTEN)
- Very Strong Family History of Breast or Ovarian Cancer
Ovarian Cancer Prophylaxis
- Risk-Reducing (Prophylactic) Bilateral Salpingo-Oophorectomy (BSO) Indications:
- BRCA1 Pathogenic or Likely Pathogenic Variant
- BRCA2 Pathogenic or Likely Pathogenic Variant
- *Only Consider Upon Completion of Childbearing
- *Some Recommend Both Total Abdominal Hysterectomy (TAH) & BSO
Surgical Options
Required Margins
- Atypia (ADH/ALH): No Margin Required
- LCIS: No Margin Required
- DCIS: 2 mm
- Invasive Carcinoma: Negative Margin (“No Ink on Tumor”)
- *If Both DCIS & Invasive Cancer are Present: Goal is “No Ink on Tumor”
- Behaves More Like Invasive Cancer
- *See Individual Sections for Further Information
Breast-Conserving Therapy (BCT)
- Definition: Partial Mastectomy (Lumpectomy)
- Generally Requires SLNB & Adjuvant Radiation Therapy (To Eradicate Microscopic Residual Disease)
- Contraindications:
- Absolute Contraindications:
- Multicentric (≥ 2 Primary Tumors in Separate Quadrants – Unable to Remove in a Single Incision)
- Recently Debated
- Diffuse Malignant Microcalcifications
- Inflammatory Breast Cancer
- Persistently Positive Margins After Multiple Attempts at Re-Excision
- Early Pregnancy
- Radiation Therapy Contraindicated
- May Consider in Select Cases in the Second/Third Trimesters
- Multicentric (≥ 2 Primary Tumors in Separate Quadrants – Unable to Remove in a Single Incision)
- Relative Contraindications:
- Connective Tissue Disease
- Such As: Scleroderma, Sjogren Syndrome or Systemic Lupus Erythematosus
- Poor Radiation Tolerance
- Large Tumor in a Small Breast
- May Have Unacceptable Cosmesis
- Connective Tissue Disease
- Not a Contraindication:
- Age
- Breast Density
- BRCA Status
- Histologic Type
- Tumor Location
- Local (Skin/Nipple) Involvement
- Lymph Node Status
- Absolute Contraindications:
- Comparison to Mastectomy:
- Lower Risk of Complications (Seroma, Lymphedema & Skin Necrosis)
- Equivalent Survival
- Mastectomy Does Not Eliminate Possibility of Local Recurrence
- Radiation Therapy Not Always Necessary After Mastectomy
- Choice of Approach Does Not Affect Decisions About Chemotherapy
- Complications:
- Chance of Local Recurrence: 2% at 10 Years (Previously Was Higher at 10% Before Improved Systemic Therapies)
- Seroma (6%)
- Hematoma
- Surgical Site Infection
- Chronic Pain
- Lymphedema
- Radiation Fibrosis
Simple (Total) Mastectomy
- Definition: Complete Removal of All Breast Tissue
- Includes Nipple-Areola Complex with Large Elliptical Excision of Skin
- Does Not Include ALND (Compared to MRM)
- Variations:
- Skin-Sparing Mastectomy
- Still Includes Nipple-Areola Complex
- Preserves the Majority of Natural Skin
- Nipple-Sparring (Subcutaneous) Mastectomy
- Preserves the Epidermis & Dermis of the Nipple-Areola Complex
- Skin-Sparing Mastectomy
- Contraindications:
- Extensive IDC
- Paget’s Disease
- Nipple Discharge
- CA < 2 cm from Nipple
- Complications:
- Seroma (14-16% – Higher than with BCT)
- Should Avoid Vigorous Shoulder Exercises in the Immediate Postoperative Period
- Surgical Site Infection
- Skin Flap Necrosis (10-18%)
- Nipple Necrosis – Seen in Nipple-Sparing Mastectomies (6%)
- Chronic Pain
- Lymphedema
- Seroma (14-16% – Higher than with BCT)
Modified Radical Mastectomy (MRM)
- Definition: Complete Removal of All Breast Tissue with an Axillary Lymph Node Dissection (ALND)
- Includes Nipple-Areola Complex with Large Elliptical Excision of Skin
- Spares Underlying Pectoralis Muscle (Compared to Radical Mastectomy)
- Complications:
- Seroma
- Surgical Site Infection
- Skin Flap Necrosis (10-18%)
- Chronic Pain
- Lymphedema
Radical (Halsted) Mastectomy
- Definition: Complete En-Bloc Removal of All Breast Tissue, Overlying Skin & Pectoralis Major/Minor Muscles with an Axillary Lymph Node Dissection (ALND)
- Rarely Preformed Anymore
- Higher Morbidity
- No Survival Benefit